Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors or Chemotherapy in Luminal B/HER2-negative Breast Cancer (DAPATH)

Compare the efficacy and safety of Dalpiciclib combined with aromatase inhibitors versus chemotherapy as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer, and explore the predictive biomarkers of the response to the two neoadjuvant therapies.

Inclusion Criteria:Patient is ≥ 18 years-old at the time of consent to participate this trialFamale stage I-IIIA breast cancer patients or T4bN0-2M0HR-positive, HER2-negtive invasive breast cancer, Ki67≥20% or PgR<20%No prior anti-cancer treatmentECOG 0-1Exclusion Criteria:Known to have other aggressive malignant tumor in the past 5 years.Bilateral breast cancer; Inflammatory breast cancer; Occult breast cancer; Distant metastasis confirmed by pathology.There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.Female patients during pregnancy or lactation.The investigator determines that subjects are not appropriate to participate in the study due to other factors.